COYA Stock Forecast & Price Target

Coya Therapeutics is viewed favorably because its Treg-modulation strategy is biologically compelling, technically straightforward, and supported by preclinical and clinical evidence showing deep immunomodulation, positive biomarkers, and signs of slowing decline in serious neurodegenerative disease. The company also benefits from FDA Fast Track Designation for COYA 302 in ALS, a cash runway guidance into 2H27 with $43.2 million at June 30, and near-term catalysts including enrollment completion expected in 4Q26, top-line ALSTARS data in 1Q27, and broader phase II data in 1Q27. If COYA 302 can deliver a clinically persuasive ALSFRS-R benefit in ALSTARS, the profile could support regulatory progress and make Coya’s inflammation-targeting approach a differentiated option in high-unmet-need diseases.

Coya Therapeutics is a clinical-stage company with no revenue-generating products, so its valuation depends heavily on unproven pipeline progress rather than recurring fundamentals. In 2Q26, operating expenses rose 11% to $7.3 million, R&D climbed 37% to $5.0 million, and the company posted a $6.6 million net loss, underscoring persistent cash burn tied to the COYA 302 ALS phase II trial. The outlook remains negative because clinical and regulatory setbacks, weak efficacy, intense competition, and likely future debt or equity financing create meaningful dilution and execution risk, while the change in fair value of convertible promissory notes added another $2.497 million burden.